Treatment-related adverse events related to SIRT or nivolumab
| System organ class, preferred term | Patients with treatment-related adverse events, no (%) | |
| Event | Any grade | Grade 3-5 |
| Related to SIRT | ||
| Hepatobiliary disorders | ||
| Hyperbilirubinemia | 8 (19) | 1 (2) |
| ALT increased | 1 (2) | 0 |
| AST Increased | 1 (2) | 0 |
| Blood and lymphatic system disorders | ||
| Thrombocytopenia | 7 (17) | 0 |
| Lymphopenia | 1 (2) | 0 |
| Infections and infestations | ||
| Liver abscess | 1 (2) | 1 (2) |
| Gastrointestinal disorders | ||
| Ascites | 1 (2) | 0 |
| General disorders | ||
| Fever | 1 (2) | 0 |
| Vascular disorders | ||
| Hematoma | 1 (2) | 0 |
| Related to nivolumab (IMAEs) | ||
| Hepatobiliary disorders | ||
| ALT increased | 5 (12) | 1 (2) |
| AST increased | 6 (14) | 1 (2) |
| Hyperbilirubinemia | 2 (5) | 0 |
| Immune hepatitis | 2 (5) | 1 (2) |
| Endocrine disorders | ||
| Hypothyroidism | 4 (10) | 0 |
| Thyroiditis | 2 (5) | 0 |
| Hyperthyroidism | 1 (2) | 0 |
| Skin and subcutaneous tissue disorders | ||
| Pruritus | 4 (10) | 0 |
| Rash | 3 (7) | 0 |
| Dermatitis | 2 (5) | 0 |
| Gastrointestinal disorders | ||
| Diarrhea | 2 (5) | 1 (2) |
| Blood and lymphatic system disorders | ||
| Anemia | 2 (5) | |
| Metabolism and nutrition disorders | ||
| Diabetes mellitus | 1 (2) | 1 (2) |
| Hyperosmolar nonketotic syndrome | 1 (2) | 1 (2) |
| Renal and urinary disorders | ||
| Renal impairment | 1 (2) | 1 (2) |
| Tubulointerstitial nephritis | 1 (2) | 1 (2) |
| Blood creatinine increased | 1 (2) | 0 |
| Musculoskeletal and connective tissue disorders | ||
| Back pain | 1 (2) | 0 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; SIRT, selective internal radiation therapy.